PEX010 Psilocybin Capsules ( 25mg psilocybin)

DRUG4 trials

Sponsors

Rigshospitalet, Region Hovedstaden, Kobenhavns Universitet, Koebenhavns Universitet

Conditions

Alcohol Use DisorderComa and other disorders of consciousness due to acute traumatic and non-traumatic brain injuryDepression

Phase 1

Boosting recovery through excitation of arousal and awareness in comatose patients: The BREA2KTHROUGH trial

WithdrawnCTIS2023-503617-30-01

RigshospitaletComa and other disorders of consciousness due to acute traumatic and non-traumatic brain injury

Target: 384Updated: 2023-11-20

Boosting recovery through excitation of arousal and awareness in comatose patients: Dose finding study (BREA2KTHROUGH DOSEFINDER)

RecruitingCTIS2023-503617-30-02

RigshospitaletComa and other disorders of consciousness due to acute traumatic and non-traumatic brain injury

Start: 2025-02-26Target: 384Updated: 2025-02-27

Can a one-off administration of psilocybin reduce alcohol intake in patients with alcohol use disorder? A randomized, double-blinded, placebo-controlled clinical trial.

RecruitingCTIS2024-517497-17-01

Region HovedstadenAlcohol Use Disorder

Start: 2023-09-01Target: 100Updated: 2026-01-13

Phase 2

The Acute and Long-term Impact of Support and Music in Psilocybin Therapy for Depression: The Psilocybin Setting Trial (PSISET)

WithdrawnCTIS2025-522961-31-00

Kobenhavns Universitet, Koebenhavns UniversitetDepression

Target: 120Updated: 2026-03-24